Cobimetinib clinical trials
Also written Cotellic, GDC-0973 and XL518.
ClinicalTrials.gov finds 122 studies for cobimetinib. How that becomes 94 here
Every study that search finds has been read, to see whether and how it gives cobimetinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 122Found by its intervention search · See all 122 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 113 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 122Give cobimetinib to participants
- −5Observe patients on it, or give it outside a trial
- −23Give it beside what is tested
- 94Test it: the count on this site
Get an email when these change. Save the cobimetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Nov 2015 · COTELLIC · NDA 206192 (FDA, Drugs@FDA)
- European Union
- 20 Nov 2015 · Cotellic · EMEA/H/C/003960 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
94 studies that test it; most in 2017 (16)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 9 |
| 2016 | 9 |
| 2017 | 16 |
| 2018 | 12 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 9 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 56
Hoffmann-La Roche (21) · Genentech, Inc. (15) · OHSU Knight Cancer Institute (4) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (3) · Fondazione Melanoma Onlus (2) · Hanmi Pharmaceutical Company Limited (2) · Peter MacCallum Cancer Centre, Australia (2)
Often tested with
Tested in the same studies.
Atezolizumab (39) · Vemurafenib (25) · Alectinib (11) · Trastuzumab (10) · Pertuzumab (10) · Bevacizumab (9) · Olaparib (8) · Entrectinib (7)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 8 most studied
New when their studies opened, with cobimetinib beside them; studies of each.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test cobimetinib, phase 3 first.
- Jun 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Hoffmann-La Roche
- Nov 2026Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationPhase 2 · City of Hope Medical Center
- Nov 2026A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2 · Genentech, Inc.
- Dec 2026A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Phase 1 · Genentech, Inc.
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Jun 2027Targeted Pathway Inhibition in Patients With Pancreatic CancerEarly Phase 1 · OHSU Knight Cancer Institute
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses cobimetinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 94
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One cohort: alone for matching tumours (FINPROVE)Written as CobimetinibReport a problem
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingPhase 2Carl AllenNCT04079179Alone in refractory Langerhans cell histiocytosisWritten as CobimetinibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One cohort: with vemurafenib for BRAF-mutated tumours (TAPUR)Written as Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)Report a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Alone, briefly before surgery, in pancreatic cancerWritten as CobimetinibReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm: with vemurafenib for BRAF V600 cancers (DETERMINE)Written as Vemurafenib in combination with cobimetinibReport a problem
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079One drug that organoid testing may choose in pancreatic cancerWritten as CobimetinibReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606One cohort: with vemurafenib for BRAF V600 tumours (CAPTUR)Report a problem
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingPhase 2Hanmi Pharmaceutical Company LimitedNCT07449754With belvarafenib, three times weekly, in NRAS-mutant melanomaWritten as CobimetinibReport a problem
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingPhase 2City of Hope Medical CenterNCT06440850With vemurafenib before radioactive iodine in thyroid cancerWritten as CobimetinibReport a problem
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05768178With vemurafenib for BRAF V600 cancers beyond melanoma (DETERMINE arm 5)Written as CobimetinibReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One cohort: with vemurafenib for matching tumours (ProTarget)Report a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956One cohort: with vemurafenib outside its approved use (IMPRESS-Norway)Report a problem
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS MutationsRecruitingPhase 2N.N. Petrov National Medical Research Center of OncologyNCT06229340One MEK inhibitor option, with hydroxychloroquine, in RAS-mutant cancersReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One cohort: with vemurafenib for matching tumours (DRUP)Written as Vemurafenib and Cobimetinib (combination treatment)Report a problem
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03600701With atezolizumab in lung cancerWritten as CobimetinibReport a problem
- Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)CompletedPhase 2University of ArkansasNCT05125471Alone in extracranial arteriovenous malformationsWritten as CobimetinibReport a problem
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025One cohort: with vemurafenib before surgery in BRAF lung cancerWritten as CobimetinibReport a problem
- BEACON - ABC in Recurrent Platinum Resistant HGSOCCompletedPhase 2Peter MacCallum Cancer Centre, AustraliaNCT03363867With atezolizumab and bevacizumab in platinum-resistant ovarian cancerWritten as CobimetinibReport a problem
- Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingPhase 2University of UtahNCT04409639Alone in RAS-mutant chronic myelomonocytic leukaemiaWritten as CobimetinibReport a problem
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03224767With vemurafenib in BRAF V600E craniopharyngiomaWritten as CobimetinibReport a problem
See all 94 studies that test cobimetinib →
Tested on its own · 11 — no other medicine in its arm
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingPhase 2Carl AllenNCT04079179Alone in refractory Langerhans cell histiocytosisWritten as CobimetinibReport a problem
- Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)CompletedPhase 2University of ArkansasNCT05125471Alone in extracranial arteriovenous malformationsWritten as CobimetinibReport a problem
- Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingPhase 2University of UtahNCT04409639Alone in RAS-mutant chronic myelomonocytic leukaemiaWritten as CobimetinibReport a problem
- Cobimetinib for BRAF-wild-type or Mutated HistiocytosesCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT04007848Against placebo in histiocytosesWritten as CobimetinibReport a problem
- Single-agent Cobimetinib for Adults With Histiocytic DisordersCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02649972Alone in adults with histiocytic disordersWritten as CobimetinibReport a problem
- Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid TumorsCompletedPhase 1/2Hoffmann-La RocheNCT02639546Alone in children and young adults with solid tumoursWritten as CobimetinibReport a problem
- A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT01249131Tablet against capsule, and the effect of food, in healthy volunteersWritten as CobimetinibReport a problem
- An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)CompletedPhase 1Genentech, Inc.NCT01249118By mouth against into a vein, in healthy volunteersWritten as GDC-0973 IV InfusionReport a problem
- A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male VolunteersCompletedPhase 1Genentech, Inc.NCT01711762A radio-labelled dose to trace how the body clears itWritten as GDC-0973Report a problem
- A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule FormulationCompletedPhase 1Genentech, Inc.NCT02136524Tablet against capsule, in healthy volunteersWritten as cobimetinibReport a problem
- A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver DamageCompletedPhase 1Genentech, Inc.NCT02300025Its levels in people with and without liver damageWritten as cobimetinibReport a problem
Tested with established drugs · 8 — they are given beside it
- Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesStatus unknownPhase 2Sunnybrook Health Sciences CentreNCT02036086With vemurafenib before surgery in stage III melanomaWritten as CobimetinibReport a problem
- A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedPhase 3Hoffmann-La RocheNCT01689519Added to vemurafenib, against placebo, in BRAF V600 melanomaWritten as CobimetinibReport a problem
- To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.Status unknownPhase 2Intergruppo Melanoma ItalianoNCT03514901Continued with vemurafenib beyond focal progression, with local treatmentReport a problem
- Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompletedPhase 2Grupo Español Multidisciplinar de MelanomaNCT02583516With vemurafenib, given continuously or intermittently, in melanomaWritten as vemurafenib and cobimetinibReport a problem
- Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesTerminatedPhase 2Melissa Burgess, MDNCT02230306With vemurafenib in active melanoma brain metastasesWritten as CobimetinibReport a problem
- A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT01277718Effect of rabeprazole on its absorption, in healthy volunteersWritten as CobimetinibReport a problem
- Study of Cobimetinib in Participants With Solid TumorsCompletedPhase 1Genentech, Inc.NCT00467779Alone, the first dose-finding study in solid tumoursWritten as cobimetinibReport a problem
- A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT01929876Effect of itraconazole on its levels, in healthy volunteersWritten as CobimetinibReport a problem
Tested in a combination · 75 — another drug in the study is under test too
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One cohort: alone for matching tumours (FINPROVE)Written as CobimetinibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One cohort: with vemurafenib for BRAF-mutated tumours (TAPUR)Written as Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)Report a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Alone, briefly before surgery, in pancreatic cancerWritten as CobimetinibReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm: with vemurafenib for BRAF V600 cancers (DETERMINE)Written as Vemurafenib in combination with cobimetinibReport a problem
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079One drug that organoid testing may choose in pancreatic cancerWritten as CobimetinibReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606One cohort: with vemurafenib for BRAF V600 tumours (CAPTUR)Report a problem
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingPhase 2Hanmi Pharmaceutical Company LimitedNCT07449754With belvarafenib, three times weekly, in NRAS-mutant melanomaWritten as CobimetinibReport a problem
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingPhase 2City of Hope Medical CenterNCT06440850With vemurafenib before radioactive iodine in thyroid cancerWritten as CobimetinibReport a problem
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05768178With vemurafenib for BRAF V600 cancers beyond melanoma (DETERMINE arm 5)Written as CobimetinibReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One cohort: with vemurafenib for matching tumours (ProTarget)Report a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956One cohort: with vemurafenib outside its approved use (IMPRESS-Norway)Report a problem
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS MutationsRecruitingPhase 2N.N. Petrov National Medical Research Center of OncologyNCT06229340One MEK inhibitor option, with hydroxychloroquine, in RAS-mutant cancersReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One cohort: with vemurafenib for matching tumours (DRUP)Written as Vemurafenib and Cobimetinib (combination treatment)Report a problem
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03600701With atezolizumab in lung cancerWritten as CobimetinibReport a problem
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025One cohort: with vemurafenib before surgery in BRAF lung cancerWritten as CobimetinibReport a problem
- BEACON - ABC in Recurrent Platinum Resistant HGSOCCompletedPhase 2Peter MacCallum Cancer Centre, AustraliaNCT03363867With atezolizumab and bevacizumab in platinum-resistant ovarian cancerWritten as CobimetinibReport a problem
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03224767With vemurafenib in BRAF V600E craniopharyngiomaWritten as CobimetinibReport a problem
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingPhase 1Genentech, Inc.NCT04835805With belvarafenib, with or without nivolumab, in NRAS-mutant melanomaWritten as CobimetinibReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342One arm: alone in MAPK-altered rare ovarian tumoursWritten as CobimetinibReport a problem
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552One cohort: with vemurafenib and atezolizumab in BRAF V600 lung cancerWritten as CobimetinibReport a problem
Showing 20 of 75. See all 75 →
Beside an established treatment under test · 5 — an approved drug, surgery or radiation is what the study tests
Tested with cobimetinib: atezolizumab 2 · Bevacizumab 1
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03181100Matched targeted partner of atezolizumab in thyroid cancer cohortsWritten as CobimetinibReport a problem
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedPhase 3Hoffmann-La RocheNCT02908672In every armBackbone with vemurafenib; the study adds atezolizumabWritten as CobimetinibReport a problem
- Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF MutationCompletedPhase 1/2Fondazione Melanoma OnlusNCT01959633In every armBackbone with vemurafenib; the study adds PEG-interferonWritten as CobimetinibReport a problem
- Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibTerminatedPhase 1Mohammed M MilhemNCT01876641In every armBackbone with vemurafenib; the study adds decitabineWritten as Vemurafenib + Cobimetinib, DecitabineReport a problem
- Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaTerminatedPhase 2Melanoma Research Foundation Breakthrough ConsortiumNCT01495988Part of standard vemurafenib-cobimetinib; the study tests adding bevacizumabWritten as CobimetinibReport a problem
Beside a new treatment under test · 10 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with cobimetinib: Nivolumab 2 · pelcitoclax 1 · XL 888 1 · ifebemtinib 1 · LY3022855 1 · atezolizumab 1 · Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 1 · ABM-1310 1
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05691504In every armPartner of new pelcitoclax in ovarian and endometrial cancerWritten as CobimetinibReport a problem
- XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02721459In every armBackbone with vemurafenib for new XL888 in melanomaWritten as CobimetinibReport a problem
- IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaCompletedPhase 1InxMed (Shanghai) Co., Ltd.NCT04109456Partner of new IN10018 in melanomaWritten as CobimetinibReport a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188Partner in one nivolumab-ipilimumab cohort in colon cancerWritten as CobimetinibReport a problem
- A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT01928394Partner in one nivolumab-ipilimumab cohortWritten as CobimetinibReport a problem
- LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03101254In every armBackbone with vemurafenib for new LY3022855 in melanomaWritten as CobimetinibReport a problem
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedPhase 1ABM Therapeutics CorporationNCT04190628Partner of new ABM-1310 in solid tumoursWritten as CobimetinibReport a problem
- T3011 in Combination With Cobimetinib in Patients With Advanced MelanomaSuspendedPhase 2ImmVira Pharma Co. LtdNCT05756556In every armPartner of new T3011 in melanomaWritten as T3011 + CobimetinibReport a problem
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedPhase 1/2Revolution Medicines, Inc.NCT03989115Partner of new RMC-4630 in solid tumoursWritten as CobimetinibReport a problem
- A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedPhase 1Genentech, Inc.NCT01656642Partner in one cohort of atezolizumab with vemurafenibWritten as CobimetinibReport a problem
Beside supportive care · 4 — a supportive treatment or test is studied
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Continued from a parent atezolizumab studyWritten as CobimetinibReport a problem
- A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedPhase 2Hoffmann-La RocheNCT02768207In every armStandard treatment after a plasma BRAF test in melanomaWritten as CobimetinibReport a problem
- Prevention of Phototoxicities in Patients Undergoing Vemurafenib TreatmentCompletedNot applicableMichele SayagNCT03108209Treatment during which sunscreen against phototoxicity is testedReport a problem
- Radiation Use During Vemurafenib TreatmentWithdrawnPhase 1University of UtahNCT01843738Named in the full title as treatment given during radiationReport a problem
One option of several · 4 — a test or a strategy chooses among drugs
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521One option in molecularly guided therapy against chemotherapyWritten as CobimetinibReport a problem
- Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03026517One BRAF-MEK option; the study tests adding phenforminReport a problem
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibTerminatedEarly Phase 1Craig L Slingluff, JrNCT02382549One MEK inhibitor option with a BRAF inhibitor; the study tests a peptide vaccineReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One option in tailored therapy against standard careWritten as CobimetinibReport a problem
Observed · 5 — patients on it are followed, or it is given outside a trial
- Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical PracticeRecruitingMelanomaPRO, RussiaNCT05402059With vemurafenib and atezolizumab in one cohort, observed in Russian practiceReport a problem
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasActive, not recruitingBlokhin's Russian Cancer Research CenterNCT07448480One MEK inhibitor option in recurrent gliomas, observedReport a problem
- Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the USCompletedPfizerNCT05260684With vemurafenib, compared with other BRAF-MEK pairs in US recordsWritten as CobimetinibReport a problem
- Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNovartis PharmaceuticalsNCT05611229With vemurafenib, among BRAF-positive melanoma treatments observedWritten as Vemurafenib+CobimetinibReport a problem
- A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])CompletedHoffmann-La RocheNCT03139513With vemurafenib in the French early access programme, observedWritten as CobimetinibReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)Nov 12, 2026NCT05125471
Codes
What other systems call cobimetinib · ClinicalTrials.gg INT006122
- MeSH (NLM) C574276cobimetinibOne source NLM
- UNII (FDA) ER29L26N1XCOBIMETINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1722365Confirmed FDA, Wikidata
- Wikidata Q15708292cobimetinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68923CobimetinibOne source FDA
- DrugBank DB05239One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574276 | cobimetinib | One source NLM |
| UNII (FDA) | ER29L26N1X | COBIMETINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1722365 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708292 | cobimetinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68923 | Cobimetinib | One source FDA |
| DrugBank | DB05239 | — | One source Wikidata |
Also registered as cobimetinib fumarate (UNII 6EXI96H8SV · RxNorm 1722380).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.